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Abstract Nanomedicine, as a relatively new offshoot of 
nanotechnology, has presented vast opportunities in 
biomedical research for developing novel strategies to treat 
diseases. In the past decade, there has been a significant 
increase in in vitro and preclinical studies addressing the 
benefits of nanomedicines. In this commentary, we focus 
specifically on the efficacy- and toxicity-related 
translational challenges of nanocarrier-mediated systems, 
and briefly discuss possible strategies for addressing such 
issues at in vitro and preclinical stages. We address 
questions related specifically to the balance between 
toxicity and efficacy, a balance that is expected to be 
substantially different for nanomedicines compared to that 
for a free drug. Using case studies, we propose a 
ratiometric assessment tool to quantify the overall benefit 
of nanomedicine as compared to free drugs in terms of 
efficacy and toxicity. The overall goal of this commentary is 
to emphasize the strategies that promote the translation of 
nanomedicines, especially by learning lessons from 
previous translational failures of other drugs and devices, 
and to apply these lessons to critically assess data at the 
basic stages of nanomedicinal research.    
Keywords Nanomedicine, Translational medicine, 
Nanotechnology, Efficacy, Toxicity 
1. Introduction 
 
The last two decades have witnessed the advent of 
nanomedicines - a powerful new component of 
nanotechnology that presents new opportunities and 
challenges in almost all specialties of medicine. There is 
very little doubt that nanotechnology and its use in 
medicine is here to stay. It can be predicted with a strong 
degree of confidence that the next few years will witness 
a further increase in the number of nanotechnology-based 
diagnostic and therapeutic applications. Currently, 
research involving nanomedicines and their potential use 
for various human conditions is being conducted at a rapid 
pace. New information relating to the synthesis, 
characterization and biological response of nanomedicines 
is being added almost every day.  
 
Nanomedicines generally involve the use of nanoparticles 
as delivery systems to transport drug to target sites, 
usually tumours or diseased tissues and cells. Being less 
than a tenth of a micron in size, nanoparticles acquire 
certain properties that make them useful in several 
avenues of medicine, such as medical imaging, drug 
delivery for enhanced bioavailability, and triggered drug 
delivery. Drugs can be encapsulated within - or surface 
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conjugated - to nanoparticles, which generally results in 
enhanced effects of the drug. Drug-loaded nanoparticles 
in particular have demonstrated enhanced efficacy in 
killing several types of tumour cells. With nanomedicinal 
technology growing out of its infancy, a number of nano-
therapeutic drugs have emerged from the commercial 
pipeline. Doxorubicin encapsulated within 
nanoliposomes (e.g., Caelyx®), PEGylated protein 
conjugates (e.g., Oncospar® and PegIntron®) and 
polymeric nanoformulations (e.g., Copaxone®) are a few 
such examples. Global investment in nanotechnology, 
specifically in healthcare related areas, has been 
increasing steadily. The National Nanotechnology 
Initiative (NNI), a US government initiative for 
promoting research and development in the area of 
nanotechnology, received $1.7 billion in the 2014 
Presidential budget [1]. Similarly, the European Union, 
Japan and China are reported to have invested $1.7 
billion, $950 million and $430 million, respectively, in 
nanotechnology initiatives [2]. Global optimism 
combined with significant international resource 
allocations to nanotechnology research, especially in 
healthcare, promises significant positive outcomes and 
has the potential to provide much-needed breakthroughs 
in modern medicine. 
 
In the past decade, there has been a significant increase in 
in vitro and preclinical studies addressing the benefits of 
complex drug delivery systems [3-5], especially 
nanoformulations of various drugs (Figure 1.). Thanks to 
these studies, we now have a much clearer (though 
incomplete) understanding regarding what it takes for 
the construction of a biocompatible nano-drug delivery 
system, its material component and related 
pharmacokinetic/pharmacodynamic parameters. Even 
though much fundamental work still remains, we have 
gathered sufficient material science and cellular and 
systems biology information to earnestly consider 
translating nano-drug formulations from bench to 
bedside. However, this is no ordinary task. While each 
nanomedicine has its own distinctive set of challenges, 
there are certain hurdles that remain common to the 
entire family of nanomedicines. The rapid uptake and 
clearance of nanoparticles by the mononuclear-phagocyte 
system, renal and biliary excretion, and cationic charge-
dependent toxicity, are a few such examples. Though 
strategies such as the surface-coating of nanoparticles 
with protein-resistant polymers [6] have been devised to 
delay clearance and prolong drug action, challenges 
concerning tissue accumulation and toxicity still remain.  
 
Currently, the primary objective of most nanomedicinal 
formulations is to enhance the pharmacokinetic 
characteristics and reduce collateral off-site effects of the 
loaded drug (Figure 2). While the objective of increasing 
efficacy and decreasing toxicity seems rather 
straightforward, the process, however, is fraught with 
challenges that are technical, biological and financial in 
nature. In this commentary, we will focus specifically on 
the efficacy- and toxicity-related translational challenges 
of nanocarrier-mediated drug delivery systems and 
briefly discuss possible strategies for addressing these 
issues at the in vitro and preclinical stages before 
attempting human translation.  
 
Figure 1. Publication count for nano-drug-related articles 
published from 1980 to 2013. A year-wise PubMed search was 
conducted with the key words 'nano-drug', nanomedicine', 
'nano-drug delivery', 'nano carrier drug delivery', and ‘targeted 
drug delivery'. Both research articles and reviews have been 
included in the above publication count. 
 
 
Figure 2. Expected role of nanomedicines: Enhancing efficacy 
and lowering toxicity 
 
2. Challenges facing the translation of nanomedicines  
 
Translating a nanomedicine formulation from a 
preclinical stage to a phase trial is a daunting task. There 
are several examples of nanomedicinal formulations with 
promising preclinical data showing enhanced efficacy, 
only to fail in clinical phase trials. The cisplatin 
encapsulated PEGylated nanoliposome (SPI-077TM) is one 
such example where in vivo studies showed enhanced 
anti-tumour activity [7]. Upon SPI-077TM administration 
in mouse cancer models, cisplatin accumulated within the 
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tumour tissue in larger concentrations and circulated in 
the blood for much longer without signs of toxicity [7]. 
An enhanced tumour regression ability and a favourable 
pharmacokinetic profile meant that SPI-077TM was a 
promising formulation for human studies. Despite such 
encouraging results, phase I-II results in patients with 
locally advanced squamous cell cancer of the head and 
neck showed negligible activity with SPI-077TM [8]. This 
lack of efficacy in patients was attributed to lower 
bioavailability and the altered release profile of cisplatin 
from SPI-077TM nanoliposomes. Though toxicity was not 
an issue (both, primate studies [9] and patient data 
demonstrated no changes in the toxicity profile), minimal 
gains in efficacy were not sufficient for successful 
translation and subsequent progression to mainstream 
clinical practice. This highlights the efficacy expectation 
that nanomedicines face as they progress through the 
translational pipeline. 
 
Another challenge in nanomedicinal research is the 
change in the drug toxicity profile after loading it onto a 
carrier [10]. Though the desirable effect of nano-
encapsulation is to decrease the toxicity profile of the 
drug, the opposite may also occur. This is especially 
true for particle-encapsulated cytotoxic drugs, which get 
sequestered primarily by the kupffer cells in the liver, 
leading to drug-induced hepatic injury. Increased drug-
induced toxicity after encapsulation has also been 
observed in locally administered particulate delivery 
systems. Local anaesthetic drugs loaded onto polymeric 
and lipid-sugar containing microspheres produced local 
muscle injury that was more intense than the drug alone 
[11]. This drug-induced muscle injury was attributed to 
the prolonged exposure of adjacent muscle tissue to the 
slowly releasing drug from the delivery system. While it 
may be difficult to control immediate toxic effects 
locally, more precise control of burst release, smart 
surface coating, ligand-mediated active targeting and 
triggered drug release systems are being developed to 
address drug-induced toxicity challenges. 
 
Another important complicating factor that arises in 
nanomedicines designed as delivery systems concerns the 
physiological effects of the nanocarrier itself. Depending 
on the size, surface charge and surface chemistry of the 
nanomaterial, there can be independent toxicity effects 
associated with the particle itself [12]. Some well-known 
nanoparticle-associated adverse effects include direct 
tissue injury, selective organ toxicity, long-term tissue 
retention, potential carcinogenic effects and immune-
mediated injury, all of which are critical factors to be 
considered in translation [10,13]. Site-directed targeting is 
a common approach to circumventing this issue, but non-
specific tissue-binding and the accumulation of 
nanomedicine in the liver, spleen and kidney remain. 
This report will not discuss the bio-mechanisms of 
nanomedicinal toxicity, since there have been several 
exhaustive reports and commentaries written on this 
topic [14-16]. However, what we will discuss is the need 
to restructure the bench-side and preclinical research 
strategies in order to focus on long-term translation while 
keeping nanomedicinal toxicity in the backdrop. We will 
address questions related specifically to the balance 
between toxicity and efficacy, a balance that is expected 
to be substantially different for nanomedicines compared 
to that for a free drug.   
 
The current nano-biotechnology approach, of first 'make 
it' and then 'screen it' [17] borrowed from traditional 
pharmaceutical industry (though necessary for the 
advancement of the field), may not be the most conducive 
for translational medicine. As an example, platinum is 
lately being re-examined as a nanoparticle carrier for 
various biological applications, including cancer [18,19]. 
It is well-known clinically that platinum is highly 
nephrotoxic [20,21], and hence one can pre-emptively 
predict that attempts to translate a platinum-based 
nanomedicinal formulations from the bench-side to the 
bed would pose nephro-toxicity challenges. A more 
prudent approach for clinical translation would be an 
'application-specific design' methodology. This would 
require the clear identification of a target profile (a 
specific disease, its subtype and the cellular target that 
needs to be modulated), an in-depth understanding of the 
biology, pathogenesis and, most importantly, 
shortcomings of the current line of management. This 
approach is well in line with previous observations that 
successfully translatable treatment modalities are more 
likely to arise from methods that are based on 'quality by 
design' [22] rather than starting from scratch. Thus, nano-
drug delivery systems designed and developed based on 
the strong biology and clinical background of a specific 
target would have a much higher probability of success in 
translation as compared to the 'make it and screen it' 
approach.  
 
While proof of concept studies demonstrating the 
advantages of several nano- and micro-sized drug 
delivery systems have been published, very few of them 
would in reality have any significant translational value 
[17,23-25]. Though many nanomedicines demonstrate 
excellent efficacious effects in vitro, they seldom hold 
ground in hostile in vivo conditions where factors such 
as blood flow, turbulence, opsonization and protein 
coating, complement activation, adhesion, immune 
reactions, pH changes, enzymatic reactions, and other 
unknown biological events, may play a major role. Most 
nanomedicinal researchers recognize the pitfalls of 
invitro experiments, and hence results established in 
preclinical animal studies are given much greater 
prominence. However, despite favourable outcomes in 
animal studies, a significant number of products fail to 
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enter clinical phase trials [26]. In the majority of such 
translation failures, disparities in the biology of animal 
disease models and the harsh subject-selection criteria of 
phase I trials are seen as the primary contributing 
factors [26]. While the challenges for translation seem 
overwhelming, lessons can be learnt from the current 
list of commercialized nanomedicines, their paths 
towards translation and by infusing a much more 
critical view of data obtained from in vitro and in vivo 
studies. In this commentary, we wish to take up one 
such basic evaluation at the in vivo and in vitro levels 
that could possibly add to the overall assessment of a 
nanomedicine. 
 
3. The Efficacy and Toxicity Dilemma  
 
Despite strong arguments in favour of nanomedicines, 
considering their relatively recent entry and the limited 
availability of long-term data, it is only prudent to be 
extra-rigorous while assessing the benefits of 
nanomedicine. From a broader perspective, 
nanomedicines are no different from any other 
therapeutic options in that they have their advantages 
and disadvantages; they are efficacious but they also 
demonstrate adverse effects - what we term as the 'yin 
and yang’ of nanomedicines. Efficacy and toxicity are two 
fundamental parameters that determine the fate of any 
medicine. In this context, a natural question that arises is 
whether the nanomedicine is better than its free drug 
counterpart in terms of efficacy and toxicity. Yet how do 
we determine whether a specific nanomedicine is better? 
Should the efficacy of the nanoformulation be better than 
the free drug? Or should the adverse effect of the former 
be lower than that of the latter? Or both? In this section, 
we argue that the benefits of nanomedicines should be 
considered taking both the efficacy and adverse effects of 
the nanomedicine and the free drug together. We propose 
an approach for both in vitro and in vivo data, and 
provide suggestions for quantifying possible treatment 
benefits by comparing: 1) toxicity and efficacy in terms of 
the ratios of nanomedicines to free drugs, and 2) 
nanomedicine-to-free drug ratios in terms of efficacy and 
toxicity. This is a rationalistic guideline for assessing the 
effective profile of a nanomedicine that could be 
incorporated into the majority of cell culture assays, ex
vivo assays and preclinical animal testing. Such 
assessments are highly relevant in the current scenario, 
where both in vitro and in vivo research examining the 
benefits of nanomedicines has only increased (Figure 1.). 
A robust, objective system that can compare both the 
positive and negative effects of nanomedicine in 
comparison to the effects of free drugs would facilitate 
the better assessment of nanomedicines at the bench and 
provide a strong checkpoint to help decide whether it 
would be worth pursuing the nanomedicinal form of the 
drug.  
In this report, we propose two simple mathematical 
approaches to examine the benefits of a nanomedicine 
versus its free drug counterpart. The first approach 
compares efficacy (E) / toxicity (T) ratios for a 
nanomedicine (E/T)Nanomedicine and a free drug (E/T)Free drug, 
while the second approach compares the ratio of the 
toxicity or efficacy of the nanomedicine (N) to that of the 
free drug (F), namely, (N/F)Efficacy and (N/F)Toxicity. Both 
ratios could be followed over time and various 
concentration ranges. Though looking at ratios may seem 
simplistic, this approach provides convenient yet 
powerful indices to assess the overall benefit of a 
nanomedicinal preparation versus that of a free drug. 
 
The (E/T) and (N/F) ratios can be easily utilized in both in
vivo and in vitro studies. For effective assessment, it is 
important that the data in the numerator and 
denominator depicting efficacy and toxicity be converted 
into a normalized percentage. The resulting ratio can then 
be used to assess the overall benefit of a free drug versus 
its nanomedicinal variant. To further elaborate on these 
ratios, we have used both hypothetical data and data 
from previously published studies to create various 
scenarios in terms of nanomedicine toxicity and efficacy 
in comparison to free drug effects. In the hypothetical 
scenarios, we establish possible toxicity and efficacy 
profiles of nanomedicines and examine the resulting 
ratios and their interpretation. In the case studies, we 
summarize published data corresponding to the efficacy 
and toxicity of nanomedicine and free drug formulations, 
followed by the conversion of individual data to a 
percentile format and the calculation of E/T and N/F 
ratios.  
 
4. Hypothetical scenario depicting possible toxicity  
and efficacy profiles of nanomedicines.  
In Figure 3, we present a few scenarios of varying efficacy 
and toxicity in the free and nanomedicinal form of the 
drug. We highlight three typical but important outcomes 
that we analyse using our proposed ratio metric system. 
In Figure 3A, we present a nanomedicine-free drug 
profile, where the efficacy of a nanomedicine and a free 
drug are similar but the toxicity profile of the 
nanomedicine is either lower (Scenario 1, Figure 3A) or 
higher (Scenario 2, Figure 3A) than the toxicity profile of 
the free drug in all the arbitrary concentration ranges. In 
scenario 1, where the efficacy of the nanomedicine is 
similar to that of the free drug and the toxicity of the 
nanomedicine is lower than that of the free drug, 
conventional plotting of the data demonstrates an 
apparent - but moderate - difference in concentration-
dependent toxicities between the free drug and the 
nanomedicine (figure 3A). However, upon plotting the 
E/T ratio of the nanomedicine and the free drug (Figure 
3B, Scenario 1), we observe that the maximal benefit from 
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the nanomedicine lies within the first two concentration 
ranges - a fact that is not distinctly apparent in Figure 3A. 
With a further increase in concentration, the 
nanomedicine E/T ratio decreases and approaches a ratio 
value closer to that of the free drug, suggesting a lowered 
benefit with an increase in concentration. Similarly, 
plotting the N/F ratio for efficacy and toxicity (Figure 3C, 
Scenario 1) exhibits values of ~1 and <1, respectively, for 
all concentration ranges, suggesting the lowered toxicity 
of the nanomedicine compared to the free drug. Scenario 
2, in Figure 3A, depicts an alternate situation with similar 
efficacy between the nanomedicine and the free drug but 
a higher nanomedicine toxicity profile. In this scenario, 
the nanomedicine E/T ratio is lower than that of the free 
drug (Figure 3B) while the N/F ratio for toxicity is >1 for 
all concentration ranges, suggesting a negative benefit 
with the nanomedicine. 
 
Unlike the E/T ratios, the N/F ratio does not indicate the 
overall benefit between a nanomedicine and a free drug, 
but it does provide an idea regarding the magnitude of 
the difference in efficacy or toxicity between a 
nanomedicine and a free drug. This information goes 
hand-in-hand with E/T ratios and needs to be considered 
in order to acquire an overall picture of how much of a 
benefit nanomedicine formulations may exert in 
comparison to free drugs.  
 
 
Figure 3. Graphs obtained from hypothetical data showing varying efficacy and toxicity profiles. Toxicity profiles (red line) of 
nanomedicines and free drugs in a hypothetical system where the efficacy (black line) of the nanomedicine is equal to (A), greater than 
(D) or less than (G) that of the free drug. The resulting E/T (B, E, H) and N/F (C, F, I) ratios were calculated and plotted as X-Y graphs.    
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Figure 4. Case Study One: Comparative analysis of a nanomedicine versus a free drug in an in vitro cancer cell line study. The cellular 
viability of the Mv4-11 cancer cell line (A) and normal bone marrow myeloid cells in response to increasing concentrations of nano- and 
free- vorinostat. The highlighted figures (A and B) have been adapted from a previously published article by Chandran et al. (2013), 
Figure 3H,I of the original manuscript. The E/T (C) and N/F (D) ratios were calculated from the cell viability data shown in (A) and (B).  
 
In another hypothetical situation, where both the 
efficacy and toxicity of a nanomedicine is higher than 
that of a free drug (Figure 3D), the nanomedicine E/T 
ratio is clearly lower than the free drug E/T ratio (Figure 
3E), despite an N/F efficacy ratio of >1 (Figure 3F) at all 
concentration ranges. This again reiterates the point that, 
despite the increased efficacy of nanomedicines, it is 
important to visualize and consider the toxicity profile 
of both nanomedicines and free drugs together with 
efficacy in order to get an overall idea regarding the 
possible benefit or drawback of nanomedicines. 
Similarly, when the data exhibits decreased efficacy as 
well as decreased toxicity (Figure 3G), it would be 
tempting to consider this as a beneficial effect of 
nanomedicine. However, the nanomedicine E/T ratio 
shows a clear reduction in benefit, while N/F ratios for 
both efficacy and toxicity are <1, suggesting that a 
nanomedicine with such an efficacy-toxicity profile 
provides no benefit. Overall, if the E/T ratio of the 
nanomedicine is greater than that of the free drug; and 
N/FEfficacy is greater than N/FToxicity, it would be 
reasonable to pursue further testing of the 
nanomedicine.  
5. Case Study One: Comparative effect of vorinostat and 
the nanomedicinal form of vorinostat on an AML cell line  
 
For our first case study, we chose data from an article by 
Chandran et al. [27] which includes a typical in vitro cell 
assay demonstrating cell proliferation activity in the 
presence of a free cancer drug (vorinostat) or else in the 
presence of nanocarrier-associated vorinostat. The original 
published figures have been slightly modified to suite the 
current article's purpose (Figure 4A,B). In the original 
article [27], the authors discuss the enhanced in vitro 
cytotoxic effect of nanoformulated-vorinostat on multiple 
acute myeloid leukaemia cell lines. For the purpose of this 
discussion, we focus specifically on the data describing the 
effect of the free and nanomedicinal forms of vorinostat on 
the cellular proliferation of Mv4-11 (an AML cell line) and 
healthy bone marrow-derived mononuclear cells. We chose 
this data specifically because they are typical for most in
vitro studies in this field as well as to highlight the 
importance of the critical interpretation of in vitro 
proliferation assays in response to nano-drugs. We utilized 
the rate of the cellular proliferation of Mv4-11 cells as 
representative of drug efficacy, and the rate of cellular 
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proliferation of normal human bone marrow-derived 
mononuclear cells (BMMCs) as representative of drug 
toxicity. In the original article, the authors observed a 
significant difference between the nano and free variants 
of a vorinostat-induced dose-dependent decrease in Mv4-
11 proliferation (Figure 4A,B), while with normal BMCCs 
the authors observed only a non-significant trend with 
nano-vorinostat being mildly more anti-proliferative than 
free-vorinostat. We only considered the means for the 
following data and derived the anti-proliferation activity 
by taking the inverse of percent cell viability (Figure 
4C,D). The E/T ratios for nano- and free-vorinostat and 
the N/F ratios for efficacy and toxicity were derived using 
values obtained for the treatment-induced anti-
proliferation activity for each group.  
 
 
Figure 5. Case Study Two: Time-dependent beneficial effect of a 
nanomedicine over a free drug in a three-week in vivo study. The E/T 
(A) and N/F (B) ratios in tumour-bearing mice treated with cisplatin-
loaded glycol chitosan nanomedicine and free-cisplatin. The data 
shown are approximate means, digitally extracted from Kim Jong-
Ho et al. (2008), Figures 5A and 6 of the original manuscript. 
 
The E/TNanovorinostat and E/TFree drug ratios showed that there 
was not much difference on the overall effect, and hence 
no major benefit between the nano and free drug 
formulations (Figure 4C). The N/FEfficacy ratio was >1 at 
lower concentrations, while the ratio was almost equal to 
1 at higher concentrations, suggesting positive in vitro 
effects in terms of efficacy at lower concentrations (but 
seemingly no difference between nano- and free-
vorinostat at higher concentrations). The N/FToxicity ratio 
hovered a little over one, which was in line with the 
slightly lower proliferation activity in normal BMCCs 
with nano-vorinostat (Figure 4D). Interestingly, the 
minimal toxicity trend with nano-vorinostat in BMCCs 
offset the 'efficacy gains' seen in Mv4-11 cells. It is worth 
mentioning that, even though the E/T and N/F ratios give 
a critical assessment regarding the combined benefit of 
nanomedicines, it is paramount that conclusions be 
drawn in relation to the whole context of the study. For 
example, in the same study, despite a seemingly benign 
effect of nano-vorinostat compared to free-vorinostat, 
under similar in vitro conditions the E/T ratio of the nano-
vorinostat was 16.6 (at a 0.5 μM concentration) as 
compared to the E/T ratio of 1.2 of cytarabine and 
daunorubicin (a free drug combination that is currently in 
clinical use). This confirms the advantage of vorinostat 
against existing drugs, whereas the specific advantage of 
its nano-version may be evident only in the actual in vivo 
scenario where the free drug (having low aqueous 
solubility or sub-optimal pharmacokinetics) would face 
challenges in circulation. Therefore, more realistic in vivo 
models are essential for evaluating the efficacy of free 
drugs versus nanoformulations. 
 
6. Case Study Two: Comparative effect of cisplatin  
the nanomedicinal form of in tumour-bearing mice  
 
In a recent study by Kim et al. [28], the authors tested the 
anti-tumour efficacy of cisplatin-loaded nanomedicine 
(glycol-chitosan nanoparticles) in tumour-bearing mice. 
Among other groups, mice administered with free-
cisplatin were used as a comparison group. Tumour size 
reduction was used as a measure of drug activity, while 
body weight and mortality were used to determine any 
adverse reaction to the treatment groups. We used 
published in vivo data from this study to calculate the 
N/FEfficacy & Toxicity ratio and the E/TNano & Free drug ratio and 
examined the comparative effect of the nanomedicine and 
free-cisplatin. We used plot digitizer software (The Free 
Software Foundation, MA, USA) to extract data from 
published figures and re-plotted the extracted data to 
calculate and display approximate efficacy and toxicity 
ratios. Since the data extracted from digitized graphs are 
approximate, we only considered the means of the 
extracted data while ignoring the standard deviation of 
each data point. We then converted the actual tumour 
volume sizes into percentiles (considering the maximum 
tumour size at the end of study in untreated controls as 
100%) and calculated the anti-tumour growth activity of 
cisplatin-loaded nanomedicine and free-cisplatin. This 
was considered as a measure of efficacy. We followed 
similar steps for calculating the E/T and N/F ratios for 
relative body-weight change, which was considered as an 
indirect measure of toxicity. The cisplatin-loaded 
nanoparticulate system exhibited nanomedicine E/T ratios 
that were similar to the free-drug E/T ratios for the first 
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five-to-six days, after which the nanomedicine shows a 
clear benefit compared to free-cisplatin (Figure 5A). 
Similarly, the cisplatin-loaded nanoparticulate system 
demonstrates an N/F efficacy ratio of >1 over a period of 
three weeks (Figure 5B), suggesting a clear benefit in 
efficacy (anti-tumour growth activity). Relative body-
weight gain during the duration of treatment 
demonstrates a N/F ratio of one for the first two weeks of 
treatment, suggesting no beneficial effect for this duration. 
However, a clear benefit in relative weight-gain is 
observed with the nanomedicine after two weeks. Overall, 
this comparative analysis demonstrates a clear benefit for 
the use of the nanocarrier-associated cisplatin over free-
cisplatin. Though a long-term experimental design would 
have provided additional translational value, the 
extrapolation of trends from this three-week study shows 
promise. The authors of this study reached similar 
conclusions, but what we intend to emphasize in this 
commentary is the need for a comparative examination of 
both efficacy and toxicity, together for free and nano-




Efficacy and toxicity form the two fundamental factors 
that determine the role of nanomedicines in clinical 
applications. With ever-increasing basic research in 
nanomedicines, one should only expect to see a few 
nanomedicines at the doorstep of clinical translation in 
coming years. While the translation of nanomedicines 
would provide an important alternative in the 
physician's arsenal, the process of translation faces 
many challenges. In this commentary, we have tried to 
highlight these challenges and we have provided 
examples of nanomedicines that showed promise in 
preclinical studies but eventually failed during clinical 
trials. We have underlined the lessons that can be learnt 
from such examples and stressed the concept of 'quality 
by design' in the development of nanomedicines. Using 
case studies, we have thus highlighted a simple but 
critical assessment tool to get a more comparative idea 
regarding the 'benefit' of using a nanomedicinal form of 
a drug. We would like to reiterate that what we have 
put forth is supplementary to current modes of 
assessment. Learning lessons from previous 
translational failures and adopting a strict and critical 
data assessment strategy at the most basic 
nanomedicinal research stage would go a long way 
towards successful human translation.  
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